ZIOPHARM Oncology, Inc. (ZIOP) down -8.14 per cent in the past week, is under coverage of 5 analysts who collectively recommend a hold rating on stock. 1 of the analysts have a buy or better rating; the 1 sells versus 0 underperforms. The 2 equity analysts who rate the stock have an average target price at $14, with individual targets ranging between $7 and $21. The shares closed last trade at $7.11, implying that analysts see shares rising about 96.91 per cent in 12 months’ time.
Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -14.44 down so far this year. A COO, CLO, and Secretary at ZIOPHARM Oncology, Inc. (ZIOP) sold shares in the company in a transaction completed on Thursday November 19, 2015. Belbel Caesar J offloaded 153,333 shares in the company at an average price of $12.84 and ended up generating $1,968,800 in proceeds. Belbel Caesar J retains 59,201 shares in the company after this transaction. A Executive Vice President R&D in the company, Lebel Francois, on Tuesday June 09, 2015 collected $506,000 from the sale of 50,000 shares at $12.84 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.
Earnings to Watch: Investors considering ZIOP stock at the going market price of $7.11/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.11 in earnings per share (EPS). That would represent a 0% year-over-year decrease. Revenue for the same period is expected to arrive at $1.76M.
Earnings Roundup: In the last fiscal quarter alone, ZIOPHARM Oncology, Inc. generated around $1.97M in revenue. That compares with the consensus estimate $1.49M. For the prior quarter revenue for the company hit $1.92M, with earnings at -$0.07/share.
Analyst Coverage: Raymond James has been a brokerage house following shares of ZIOPHARM Oncology, Inc. (ZIOP), so its rating change is noteworthy. The stock was initiated at Mkt Perform, wrote analysts at Raymond James, in a note issued to clients on Thursday June 02, 2016. There was another key note issued by Mizuho on Tuesday March 10, 2015. The firm lowered its rating on ZIOP from Buy to Neutral.
Price Momentum: Despite the -1.66% decrease in value, the stock’s new closing price represents a -52.38% fall in value from company’s one year high of $14.93. The stock is currently holding above its 50 day moving average of $-7.41 and below its 200 day moving average of $7.45. Over the last three months and over the last six months, the shares of ZIOPHARM Oncology, Inc. (ZIOP), have changed -19.38% and 7.77%, respectively.